Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T⃰

Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T⃰

Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR) recommended for patients with metastatic renal cell carcinoma (mRCC) who progressed on previous vascular endothelial growth factor (VEGF) receptor-tyrosine kinase inhibitor therapy. Efficacy of everolimus in p...

Full description

Bibliographic Details
Main Authors:	I. Tsimafeyeu, A. Snegovoy, S. Varlamov, S. Safina, I. Varlamov, L. Gurina, L. Manzuk
Format:	Article
Language:	Russian
Published:	ABV-press 2015-06-01
Series:	Onkourologiâ
Subjects:	everolimus bevacizumab interferon metastatic renal cell carcinoma resistance to anti-vegf therapy
Online Access:	https://oncourology.abvpress.ru/oncur/article/view/451

Similar Items

Five-year overall survival of metastatic renal cell carcinoma patients treated with everolimus after progression on bevacizumab: a prospective multicenter study CRAD001LRU02T
by: S. Z. Safina, et al.
Published: (2018-01-01)

Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
by: Vinay Mathew Thomas, et al.
Published: (2019-01-01)

Influence Of The Number Of Platelets And Hemoglobin Concentrations In Predicting The Development Of Proteinuria Induced By The Administration Of Bevacizumab
by: Dabanovic Vera
Published: (2015-06-01)

The Effect of Intravitreal Bevacizumab on Apoptosis of Rat Retina Cells
by: Özcan Kayıkçıoğlu, et al.
Published: (2013-01-01)

Enhancement of radiation response with bevacizumab
by: Hoang Tien, et al.
Published: (2012-04-01)

The role of bevacizumab in the treatment of patients with ovarian and cervical cancer
by: S V Khokhlova
Published: (2017-01-01)

Use of Bevacizumab in the Treatment of Corneal Neovascularization
by: Tuba Çelik, et al.
Published: (2015-01-01)

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
by: Levin PA, et al.
Published: (2017-04-01)

Bevacizumab intravítreo como tratamiento de maculopatías miópicas neovasculares
by: Dana Martinez M, et al.
Published: (2017-07-01)

Opportunities and Challenges for Successful Use of Bevacizumab in Pediatrics
by: Amy eBarone, et al.
Published: (2013-04-01)

Bevacizumab treatment of meningeal melanoma metastases
by: Trude G. Simonsen, et al.
Published: (2020-01-01)

Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
by: Doan T. M. Ngo, et al.
Published: (2020-08-01)

Short-term intraocular pressure changes after intravitreal bevacizumab injection
by: Ali Dehghani, et al.
Published: (2014-06-01)

Intravítrea de bevacizumab en el edema macular secundario a oclusión venosa de rama retiniana
by: Caridad Chiang Rodríguez, et al.

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
by: Liu J, et al.
Published: (2019-11-01)

Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
by: Shakila Jabeen, et al.
Published: (2018-11-01)

The effects of intravitreally injected bevacizumab on the retina and retina pigment epithelium: experimental in-vivo electron microscopic study in intact versus vitrectomized eyes
by: Kocak Nilufer, et al.
Published: (2010-12-01)

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma
by: Christophe Lallemand, et al.
Published: (2020-10-01)

Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
by: Joel Hanhart, et al.
Published: (2017-10-01)

Utility of bevacizumab in advanced hepatocellular carcinoma: A veterans affairs experience
by: Max M. Wattenberg, et al.
Published: (2019-04-01)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
by: Tariq Al-Debasi, et al.
Published: (2017-04-01)

Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab
by: Shakarchi FI, et al.
Published: (2018-12-01)

Necrotizing enterocolitis after intravitreal bevacizumab in an infant with Incontinentia Pigmenti – a case report
by: S. Kunzmann, et al.
Published: (2019-10-01)

Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer
by: Mohsin Hamid, et al.
Published: (2018-05-01)

Inyección intravítrea de bevacizumab vs. acetato de triamcinolona en el edema macular secundario a oclusión de rama venosa retiniana
by: Caridad Chiang Rodríguez, et al.

Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question
by: Alessandro Ottaiano, et al.
Published: (2021-09-01)

The Role of Everolimus in Renal Cell Carcinoma
by: Malek Meskawi, et al.
Published: (2015-12-01)

One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
by: Ali Salimi, et al.
Published: (2021-01-01)

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
by: Yusuke Funakoshi, et al.
Published: (2020-12-01)

Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities
by: Aysegül Tura, et al.
Published: (2019-06-01)

Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy
by: Rahmawati Minhajat, et al.
Published: (2021-05-01)

Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy
by: I. G. Kim, et al.
Published: (2018-01-01)

Preparation and study of two kinds of ophthalmic nano-preparations of everolimus
by: Zhan Tang, et al.
Published: (2019-01-01)

Selection of the anti-angiogenesis therapy for the first-line chemotherapy in advanced ovarian cancer
by: S V Khokhlova
Published: (2014-03-01)

Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus
by: Ahmed M. Alkhunaizi, et al.
Published: (2020-01-01)

Influence of vitreal reflux on intraocular pressure after intravitreal application of bevacizumab
by: Đogatović Nebojša, et al.
Published: (2020-01-01)

Analysis of early use of everolimus with low-dose calcineurin inhibitors in kidney transplant recipient
by: I. G. Kim, et al.
Published: (2019-10-01)

Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC
by: I. А. Dzhanyan, et al.
Published: (2021-06-01)

Interstitial pneumonitis caused by everolimus treatment
by: Nilufer Aykac Kongar, et al.
Published: (2016-03-01)

Symptomatic improvement using everolimus in infants with cardiac rhabdomyoma
by: Bhargavi Dhulipudi, et al.
Published: (2019-01-01)